Featured Research

from universities, journals, and other organizations

Estrogen–progestin Replacement Does Not Increase Stroke Risk

Date:
February 12, 2001
Source:
American Heart Association
Summary:
Hormone replacement therapy with estrogen and progestin does not alter the risk of stroke in postmenopausal women with heart disease, according to a report in Circulation: Journal of the American Heart Association.

DALLAS, Feb. 6 – Hormone replacement therapy with estrogen and progestin does not alter the risk of stroke in postmenopausal women with heart disease, according to a report in today’s Circulation: Journal of the American Heart Association.

Researchers with the Heart & Estrogen–progestin Replacement Study (HERS) found that the hormone therapy did not significantly increase or decrease the risk of stroke or transient ischemic attacks (TIAs), sometimes called “ministrokes,” in women who received it.

“HERS is the first clinical trial of postmenopausal hormone therapy to examine whether such therapy affects the risk of TIAs and stroke. The bottom line is that the decision to use or not use hormone therapy should be based on its known risks and benefits, and not on any presumed effect on stroke risk,” says Joel A. Simon, M.D., the paper’s lead author and a scientist at the University of California, San Francisco, as well as a physician at the Veterans Affairs Medical Center.

An editorial in today’s Circulation calls the findings “surprising” when one considers the well-documented role of estrogen as a vasoprotectant, and that hormone replacement therapy is known to reduce various fats in the blood. Also, animal studies have suggested that estrogen can protect against strokes, say Todd Tolbert, M.D., and Suzanne Oparil, M.D., of the University of Alabama at Birmingham, the editorial’s authors.

Stroke is a leading cause of death and disability, particularly among older women, many of whom use the estrogen–progestin combination to treat the symptoms of menopause and for the prevention of osteoporosis.

Previous studies that assessed the therapy’s stroke risk had yielded mixed results. Some showed a benefit, some found no benefit, and the highly regarded Framingham Heart Study suggested an increased risk of stroke, at least among cigarette smokers. None of these studies, however, was a randomized, controlled clinical trial.

The HERS trial was primarily designed to examine whether the estrogen–progestin combination would prevent a recurrent heart attack or hospitalization for unstable (worsening) angina in postmenopausal women with heart disease. However, HERS also included a number of secondary goals, one of which was to determine the therapy’s impact on stroke and TIAs.

In 1993 and 1994, researchers enrolled 2,763 postmenopausal women with known heart disease in the HERS trial, which was conducted at 20 medical centers across the United States. Half the women received the estrogen–progestin combination and half took a placebo.

The women were followed for an average of 4.1 years and the heart results were reported in 1998.

“The overall heart attack findings were that postmenopausal hormone therapy caused an increase in coronary events during the first year of the study and then subsequent decreases, so that when the study ended, there was no difference between the two groups,” Simon says.

The stroke study found that 149 of the HERS participants suffered a total of 165 strokes, of which 26 were fatal. Eighty-five percent were ischemic strokes, caused by a blockage in a carotid artery, which carries blood to the brain; 8 percent were hemorrhagic strokes, which result from a bleeding or burst blood vessel. Researchers could not determine the type of stroke in the remaining participants.

After analyzing the data, the HERS team found that the estrogen–progestin therapy did not significantly increase or decrease the risk of strokes or TIAs. Nor did the therapy affect the risk of either ischemic or hemorrhagic strokes when examined separately.

By the end of HERS, 7 percent of the women on the hormone therapy suffered a stroke compared to 5 percent of those receiving a placebo. “That was not a statistically significant difference, and could have resulted from chance,” Simon says.

He cautions that the HERS findings may not apply to women taking estrogen without progestin or to postmenopausal women taking the combination therapy who do not have heart disease. The HERS team also looked at the risk factors for stroke and found an increased risk of stroke with older age, high blood pressure, diabetes, current cigarette smoking, and a form of irregular heart beat called atrial fibrillation.

The researchers continue to follow the women who participated in HERS as part of what is known as HERS II. “We have another two to three years of observations,” Simon says. “We should be able to update this paper in another year or so to see whether these findings have changed.”

Co-authors are Judith Hsia, M.D.; Jane A. Cauley, Dr.P.H.; Cynthia Richards, M.D.; Fran Harris, M.S.; Josephine Fong, M.S.; Elizabeth Barrett-Connor, M.D.; and Stephen B. Hulley, M.D.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Estrogen–progestin Replacement Does Not Increase Stroke Risk." ScienceDaily. ScienceDaily, 12 February 2001. <www.sciencedaily.com/releases/2001/02/010206081113.htm>.
American Heart Association. (2001, February 12). Estrogen–progestin Replacement Does Not Increase Stroke Risk. ScienceDaily. Retrieved September 21, 2014 from www.sciencedaily.com/releases/2001/02/010206081113.htm
American Heart Association. "Estrogen–progestin Replacement Does Not Increase Stroke Risk." ScienceDaily. www.sciencedaily.com/releases/2001/02/010206081113.htm (accessed September 21, 2014).

Share This



More Health & Medicine News

Sunday, September 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins